<DOC>
	<DOCNO>NCT00255268</DOCNO>
	<brief_summary>To evaluate efficacy , safety survival two treatment regimen : Continuous Intermittent Maximum Androgen Blockade , use goserelin bicalutamide patient prostate cancer . Primary endpoint time progression . Fifteen patient evaluate . QoL evaluation also include .</brief_summary>
	<brief_title>CMAB v IMAB Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Histological diagnosis D2 Adenocarcinoma , Naivety treatment Valuable bone metastasis Hematological , liver renal toxicity Grade IV Severe active infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>